Table 1.

Studies reporting types and frequency of major thrombotic events in patients with primary myelofibrosis

Characteristics	Cervantes et al. [6]	Kaifie et al. [19]	Rupoli et al. [8]	Barbui et al. [13]	Elliot et al. [12]	Buxhofer-Ausch et al. [14]	Buxhofer-Ausch et al. [38]	Barosi et al. [39]
Total no. of pts.	155 (Included fibrotic PMF)	109 (Included fibrotic PMF)	72 (26 prefibrotic and 42 fibrotic PMF)	707 (Included fibrotic PMF)	205 (Included fibrotic PMF)	264 (Early/prefibrotic PMF)	77 (Prefibrotic PMF)	132 (prefibrotic PMF) 551 (Fibrotic PMF)
F/u duration	4.2 yrs. (mean)	25 yrs.**	7.08 yrs. (median)	35 yrs.	2.6 yrs. (median)	6.2 yrs. (median)	9.5 yrs.	At or in the year before diagnosis
No. of patients with thrombotic events (%)	18 (11.6)	NR	NR	47 (6.64) nonfatal and 12 fatal (1.69)	22 (10.7)	42 (15.91) nonfatal 13 (4.92) fatal	NR	40 (30.3) Prefibrotic PMF 37 (6.7) Fibrotic PMF
No. of events	31	34	22	59	33	NR	21	NR
VTE*	11	17	11	31	24	NR	NR	36 (90) Prefibrotic PMF 34 (92) Fibrotic PMF
ACS	4	7	4	7	4	NR	NR	NR
Stroke/TIA	7	7	3	13	4	NR	NR	NR
PVD	7	NR	NR	7	1	NR	NR	NR
Others	1(CRAO) 1 (cerebral thrombosis)	NR	3 (CRAO) 1 (cerebral thrombosis)	1 (sudden death)	NR	NR	NR	2 (5) cerebral thrombosis and 2 (5) arterial thrombosis Prefibrotic PMF 3 arterial thrombosis Fibrotic PMF

^*VTE included DVT/PE, portal vein thrombosis and Bud-Chiari syndrome.

^**Also included events at diagnosis and follow up. NR = not reported.